Armata Pharmaceuticals Inc (ARMP)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $111.21M
Last updated: Nov 17, 2026 at 4:16 PM ET
Armata Pharmaceuticals Inc (ARMP) Statistics
Armata Pharmaceuticals (ARMP) has a market cap of $111.21M and an enterprise value of $314.36M. It kept -1464.54% of revenue as net income over the last 12 months. Revenue grew 49.49% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 182.68% above the market cap, as debt exceeds cash.
| Market Cap | $111.21M |
|---|---|
| Enterprise Value | $314.36M |
| Latest price (Nov 17, 2026) | $2.63 |
Key Dates
The next earnings report is expected on Mar 17, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 17, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 12.9x. Its year-end P/S ranged from 7.7x to 66.8x from 2016 to 2025.
| P/S Ratio | 12.9x |
|---|---|
| Forward P/S | 33.7x |
Price Statistics
The stock is down 64.07% over 52 weeks and trades 28.53% below its 50-day average.
| Beta (1Y) | 1.03 |
|---|---|
| 52-Week Change | -64.07% |
| 1-Month Change | -14.33% |
| 3-Month Change | -48.13% |
| 6-Month Change | -68.91% |
| 5-Year Change | +2.50% |
| 10-Year Change | -98.02% |
| Total Return (1Y) | -64.07% |
| Total Return (3Y CAGR) | +5.81% |
| Total Return (5Y CAGR) | -7.63% |
| Return vs SPY (1Y) | -73.33% |
| Max Drawdown (1Y) | -82.23% |
| Max Drawdown (3Y) | -82.23% |
| Sharpe Ratio (1Y) | -0.84 |
| Correlation with SPY (1Y) | 0.12 |
| 50-Day Average | $3.68 |
| 200-Day Average | $6.83 |
| 52-Week Range | $2.75 to $14.98 |
| RSI (14 Days) | 37.5 |
| Average Volume (20 Days) | 87.68K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.12x current liabilities.
| Current Ratio | 0.12x |
|---|---|
| Quick Ratio | 0.12x |
Returns and Efficiency
Return on invested capital is -184.64% over the last 12 months.
| Return on Assets (ROA) | -130.98% |
|---|---|
| Return on Invested Capital (ROIC) | -184.64% |
| ROA (5Y Average) | -77.97% |
| Asset Turnover | 0.09x |
Scores
ARMP has an Altman Z-Score of -14.42, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -14.42 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $7.55M over the last 12 months.
| Revenue | $7.55M |
|---|---|
| Revenue Growth (YoY) | +49.49% |
| Gross Profit | $7.55M |
| Operating Income | -$40.30M |
| Pretax Income | -$110.65M |
| Net Income | -$110.65M |
| EBIT | -$110.65M |
| Reported EPS (TTM) | -$4.18 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $18.32M |
|---|---|
| Total Debt | $221.47M |
| Net Debt | $203.15M |
| Net Debt Per Share | $5.46 |
| Working Capital | -$164.18M |
| Shareholder Equity | -$174.13M |
| Tangible Book Value | -$187.87M |
| Total Assets | $84.48M |
| Total Liabilities | $258.61M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $223.00K of capital spending, operating cash flow left -$26.86M of free cash flow.
| Operating Cash Flow | -$26.64M |
|---|---|
| Capital Expenditures | $223.00K |
| Free Cash Flow | -$26.86M |
| FCF Per Share | -$0.72 |
| Depreciation and Amortization | $2.04M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -533.46%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -533.46% |
| Pretax Margin | -1464.54% |
| Net Margin | -1464.54% |
| EBIT Margin | -1464.54% |
| FCF Margin | -355.54% |
Growth
Revenue fell 3.80% a year over 3 years.
| Revenue Growth (3Y CAGR) | -3.80% |
|---|---|
| Revenue Growth (5Y CAGR) | +42.90% |
Dividends and Yields
ARMP does not pay a dividend. Its free cash flow yield is -27.47%.
| FCF Yield | -27.47% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-14 reverse split on May 10, 2019.
| Last Split Date | May 10, 2019 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:14 |
Peer Position
Against 8 similar companies, ARMP has the 4th highest P/S.
P/S RatioPeer median 5.1x
ROICPeer median -51.32%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +2.54%
| P/S Ratio | 12.9x vs 5.1x median |
|---|---|
| ROIC | -184.64% vs -51.32% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +49.49% vs +2.54% median |
Analyst Forecast
Consensus estimates put revenue growth at -25.12% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -25.12% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About ARMP
What is ARMP's market cap?
Armata Pharmaceuticals has a market cap of $111.21M. Its enterprise value, which adds debt and subtracts cash, is $314.36M.
How many shares of ARMP are outstanding?
Armata Pharmaceuticals has 37.18M shares outstanding. The count is up 2.64% from a year earlier.
Does ARMP pay a dividend?
No. Armata Pharmaceuticals does not pay a dividend.
How much debt does ARMP have?
Armata Pharmaceuticals has $221.47M of total debt and $18.32M of cash and equivalents, a net debt position of $203.15M.
ARMP pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors